Why is AmpC beta-lactamase clinically important for interpretation of cephalosporin susceptibility?

• A. AmpC can confer resistance to many cephalosporins and is not reliably inhibited by clavulanic acid, affecting interpretation
• B. AmpC inhibitor enhances penicillin activity
• C. AmpC only affects carbapenem susceptibility
• D. AmpC is absent in most Gram-negative rods

Answer: (D)

AmpC beta-lactamases change how we read cephalosporin susceptibility because they can directly neutralize many cephalosporins and are not reliably blocked by common inhibitors like clavulanic acid. If a bacterium carries AmpC, it may appear susceptible to certain cephalosporins in routine tests, but in real infections the enzyme can be expressed and expanded, leading to treatment failure. AmpC can be inducible or derepressed, so prior exposure to beta-lactams can ramp up production and shift an organism from susceptible to resistant during therapy.

These enzymes are found in a number of clinically important Gram-negative species, so you can’t assume they’re absent just because of the organism’s group. Because clavulanic acid doesn’t effectively inhibit AmpC, relying on beta-lactamase inhibitors to “rescue” cephalosporins often won’t work against AmpC producers. Some newer inhibitor combinations (like those with avibactam) can curb AmpC, but this is a key reason labs and clinicians interpret cephalosporin susceptibility with caution when AmpC is a possibility.

In short, AmpC presence can mask true resistance patterns to cephalosporins and impact treatment decisions, which is why it’s a clinically important consideration in interpretation.